Zura Bio Announces Robert Lisicki as CEO and Director
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: Business Wire
- Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director- Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience- Outstanding product development and commercialization track record across a number of leading I&I therapies spanning nearly 30 years HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio. The Company previously announced Mr. Lisicki's appointment and the commencement of a seamless transition process with Founding CEO, Dr. Someit Sidhu. This transition marks a key milestone in the company’s journey towards building a leading immunology company.This press release features multimedia. View the full release here: https://www.businessw
Show less
Read more
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio Announces Oversubscribed $112.5 Million Private PlacementBusiness Wire
- Zura Bio Limited (NASDAQ: ZURA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $16.00 price target on the stock, down previously from $17.00.MarketBeat
- Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive OfficerBusiness Wire
- Zura Bio Announces Participation at March ConferencesBusiness Wire
ZURA
Sec Filings
- 4/24/24 - Form 4
- 4/24/24 - Form 4
- 4/24/24 - Form 4
- ZURA's page on the SEC website